To determine if there are ways to predict which men will get prostate cancer, if there are ways to predict how a prostate cancer will develop (for example, slow or rapid growth) and why there are differences in prostate cancer among men from different ethnic backgrounds.
We will expand and enhance our cohort of men at risk for prostate cancer by increasing enrollment of men at greater risk of prostate cancer and at a higher risk of high-grade prostate cancer.
a. We will maintain follow-up and accrual of multi-ethnic, multi-racial cohort of men in the current SABOR cohort for prostate cancer outcomes
b. Maintain collection of wide range of biologic samples for this cohort and perform validation studies as new biomarkers are identified. Biologics gathered on patient visits are serum (at enrollment, annually and cancer dx.), whole blood, buffy coat (enrollment and cancer dx.) and PSA (enrollment, annually, and cancer dx.).
c. Maintain collection of extensive demographic and other risk factor data. Data elements gathered on cohort are date of birth, race, ethnicity, family history of PCA and other cancers, medical history, surgical history, current medications, AUA score, diabetes status, NSAID usage, prostate-related procedures and treatments
d. Additional biologics will be collected for prospective biomarker studies. Examples may include post-DRE urine collections or blood specimens with specific processing requirements.
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
Thank you to everyone who helped make the 27th EDRN Steering Committee Meeting a success. We look forward to seeing everyone at the 9th EDRN Scientific Workshop from September 8-11, 2014 in Washington D.C.